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aim: Using routine hemoglobin A1c (HbA1c) testing to describe the prevalence, charac-
teristics, and length of stay (LOS) of psychiatry inpatients with type 2 diabetes compared 
to those with pre-diabetes and those without diabetes.
Methods: In this prospective observational study, all inpatients aged greater than 
30 years admitted to the Austin Health Psychiatry Unit, a major tertiary hospital, affiliated 
with the University of Melbourne, between February 2014 and April 2015 had routine 
HbA1c testing as part of the Diabetes Discovery Initiative. Patients were divided into 
three groups: diabetes (HbA1c ≥ 6.5%, 48 mmol/mol), pre-diabetes (HbA1c 5.7–6.4%, 
39–46 mmol/mol), or no diabetes (HbA1c ≤ 5.6%, 38 mmol/mol). Baseline characteris-
tics, co-morbidities, psychiatric illnesses, and treatment were recorded.
results: There were a total of 335 psychiatry inpatients (median age 41 years). The 
most prevalent diagnoses were schizophrenia, depression, and substance abuse. Of 
the 335 psychiatric inpatients, 14% (n = 46) had diabetes and 19% (n = 63) had pre- 
diabetes, a prevalence threefold greater than in the aged matched general population. 
Compared to inpatients with pre-diabetes and no diabetes, those with diabetes were 
older and were at least twice as likely to have hypertension, obesity, and hyperlipidemia 
(all p ≤ 0.002). In multivariable analyses, diabetes was associated with increasing age 
(p =  0.02), substance abuse (p =  0.04), dyslipidaemia (p =  0.03), and aripiprazole 
use (p = 0.01). Patients with diabetes also had a 70% longer expected LOS (95% CI: 
20–130%; p = 0.001), compared to those with pre-diabetes and no diabetes.
conclusion: Despite relative youth, one-third of all psychiatric inpatients above the age 
of 30 have diabetes or pre-diabetes. Presence of diabetes in psychiatric inpatients is 
associated with older age, substance abuse, and longer LOS. Routine inpatient HbA1c 
testing provides an opportunity for early detection and optimization of diabetes care.
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inTrODUcTiOn
Diabetes and mental illness are major causes of disability and 
mortality and consume a significant aspect of the Australian 
health budget (1, 2). The age-standardized prevalence of type 2 
diabetes in Australia has doubled over the last decade according 
to the Australian Institute of Health and Welfare Data, with 4.2% 
of population having diabetes between 2011 and 2012 compared 
to 1.5% in 1989–90 (3). We recently showed that approximately 
one-third of general inpatients aged >54 years admitted to our 
hospital had type 2 diabetes (4). A recent Melbourne Public 
Hospitals Diabetes Inpatient Audit revealed the prevalence of 
diabetes ranged from 16 to 35% in different hospitals across the 
greater metropolitan region (5).
Likewise, the prevalence and effects of mental illness are many-
fold. Many Australians experience mental illness at some point in 
their lives (6). In a large Australian survey of approximately 1,800 
community-dwelling people with psychotic illness, approximately 
20% had diabetes (6). This is a concern, given the relative youth of 
people affected by both diabetes and psychosis (~88% were aged 
less than 55 years) and that the age-matched prevalence of type 2 
diabetes in the community at 55 years was only 8% (3). The survey 
examined patients with psychotic disorders in the community, 
and there are limited data in the inpatient setting. Furthermore, 
the survey did not delineate additional clinical characteristics in 
the cohort of patients with diabetes (6). There are no Australian 
data on the prevalence of diabetes and pre-diabetes in psychiatry 
inpatients.
Psychiatry inpatients are likely to be more vulnerable to dia-
betes, largely because of the acuity of the mental illness as well as 
the likelihood they will be exposed to higher doses or multiple 
medications that increase diabetes risk (6).
Diabetes and mental illness share a bidirectional interface 
where both influence each other (7, 8). This is important to appre-
ciate when trying to understand the underlying pathophysiology 
and characteristics of patients who might be at increased risk. 
Many studies have shown a link between antipsychotic medica-
tion and impaired glycemia. A systematic review and meta-
analysis undertaken in 2008 examined 11 studies to date (9). It 
demonstrated that the relative risk of diabetes in patients with 
schizophrenia prescribed second-generation versus first-gener-
ation antipsychotics was 1.32 (95% CI 1.15–1.51) (9). However, 
this observation is likely to be biased due to the methodological 
limitations in many of the studies included (9).
Measuring hemoglobin A1c (HbA1c) as a means of identify-
ing patients with diabetes is now recommended by the American 
Diabetes Association (ADA), as it is considered to be a more 
stable parameter, less affected by factors, such as fasting status, 
glucocorticoid use, or stress hyperglycemia (10, 11). In a small 
study of people with mental illness treated with antipsychotic 
medications in the community, HbA1c measurements detected a 
greater number of cases with pre- diabetes or diabetes, compared 
with the use of the fasting blood glucose criteria (12). Little has 
been documented about the use of HbA1c in the inpatient popu-
lation with severe mental illness.
Using routine HbA1c testing, the aim of this study was, there-
fore, to determine the prevalence, characteristics, and length of 
stay (LOS) of psychiatry inpatients with diabetes compared to 
those with pre-diabetes or without diabetes.
MaTerials anD MeThODs
All patients admitted to the inpatient psychiatry unit at Austin 
Health, a major tertiary hospital, affiliated with the University 
of Melbourne, during the study period (February 2014 to April 
2015) above the age of 30 were included in this prospective obser-
vational study. During the 14-month study period, all inpatients 
underwent HbA1c testing on admission via Cerner Millennium 
Information System Program, as part of routine clinical care as 
part of the Diabetes Discovery Initiative (4). Cerner Millennium 
Information System Program is the electronic health system used 
at Austin Health. We wrote a “discern rule” to identify all inpatient 
admissions with the following eligibility criteria: age ≥ 30 years, 
acute psychiatric unit admission, and no HbA1c recorded within 
3 months. If these criteria were satisfied, an automatic request for 
HbA1c was generated for routine blood collection. All HbA1c 
results were reported via Cerner and were accessible to the 
patients’ treating clinicians. As part of the Diabetes Discovery 
Initiative, all inpatients with HbA1c ≥ 8.5% (69 mmol/mol) were 
automatically reviewed by the endocrinology team to intensify 
diabetes treatment, screen for complications, and optimize 
management (4). A paragraph describing the HbA1c result and 
its interpretation was automatically inserted into each discharge 
summary to patients’ local doctors (4).
Baseline characteristics, including demographic data such as 
age, sex, residence, marital status, employment, drug, and alco-
hol history were collected. Information regarding comorbidities 
was obtained from each patient’s medical record to calculate the 
Charlson Index score without diabetes. This validated method 
of weighting the impact of chronic disease, assigns each chronic 
condition a score of 1, 2, 3, or 6, depending on severity and 
impact on mortality (4). Specific comorbidities, including diabe-
tes, hypertension, obesity (using weight and body mass index), 
and dyslipidemia, were recorded. If the patient had diabetes, 
information was collected on diabetes duration and treatment.
Data on the diagnosis of psychiatric illnesses were collected 
using the following classification: schizophrenia, schizoaffective 
disorder, bipolar affective disorder, depression, other psychosis, 
substance abuse, eating disorders, and other diagnoses. Duration 
of illness and treatment data were documented. Patients with 
two or more psychiatric diagnoses were noted. Psychotropic 
medications were categorized as anti-depressants, mood stabiliz-
ers, typical or atypical anti-psychotics, and both. Antipsychotic 
medication type was recorded.
Biochemical laboratory values (HbA1c, haemoglobin, cre-
atinine, estimated glomerular filtration rate, and fasting lipid 
profile) were extracted from medical records within three months 
of the admission date. The length of inpatient stay was recorded.
For patients who had multiple admissions, only the data from 
the initial admission was included in this study. This study was 
carried out in accordance with the recommendations of Austin 
Health Research Ethics Committee (LNR/15/Austin/41), who 
waived the need for informed consent for a planned practice 
change agreed to by the hospital senior medical staff members 
Table 1 | Patient characteristics by diabetes status.
clinical characteristics N Diabetes Pre-
diabetes
no 
diabetes
p-
value*
Number (%) 335 46 
(13.7%)
63 
(18.8%)
226 
(67.5%)
Gender, male (%) 335 32 (70%) 40 (64%) 123 
(54%)
0.106
Unemployed (%) 335 41 (89%) 53 (84%) 164 
(73%)
0.017
Median (IQR) age (years) 335 49 (39–62) 46 
(36–55)
40 
(34–48)
<0.001
Median (IQR) (HbA1c) (%) 335 7.3 
(6.2–8.7)
5.8 
(5.7–5.9)
5.4 
(5.2–5.5)
<0.001
Median (IQR) HbA1c (mmol/
mol)
335 56 (44–72) 40 
(39–41)
36 
(33–37)
<0.001
Median (IQR) duration of 
psychiatric illness (years)
335 12 (6–18) 10 (4–19) 9 (3–18) 0.215
Median length of stay (IQR) 
(days)
335 29 (14–81) 21 (9–26) 17 (9–31) 0.003
Charlson Index of 
co-morbidities (IQR) (score)
335 1 (1–2) 0 (0–1) 0 (0–0) <0.001
Hypertension (%) 335 10 (22%) 9 (14%) 14 (6%) 0.002
Hyperlipidemia (%) 335 13 (28%) 6 (10%) 14 (6%) <0.001
Obesity (%) 301 20 (44%) 15 (23%) 38 (17%) 0.001
Continuous explanatory variables were summarized as medians with interquartile 
ranges (IQRs) and compared with the use of Kruskal–Wallis tests and categorical 
explanatory variables were reported as percentages and compared with χ2 tests. All p 
values for three group comparisons were calculated from two-tailed tests of statistical 
significance and *p < 0.05 was regarded as statistically significant.
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as part of the Austin Health Diabetes Discovery Initiative. The 
protocol was approved by the Austin Health Research Ethics 
Committee.
Patients were categorized into three glycemic categories 
according to the ADA guidelines using HbA1c definitions as fol-
lows: “No diabetes” defined as HbA1c less than or equal to 5.6% 
(38 mmol/mol), “Pre-diabetes” defined as HbA1c greater than or 
equal to 5.7% and less than or equal to 6.4% (39–46 mmol/mol), 
and “Diabetes” defined as HbA1c greater than or equal to 6.5% 
(48 mmol/mol) (13).
statistical Methods
Glycemic categories were compared for baseline characteristics, 
psychiatric diagnosis, duration of psychiatric illness, psychotropic 
medication type, and LOS. Continuous explanatory variables 
were summarized as medians with interquartile ranges (IQRs) 
and compared with the use of Wilcoxon tests or Kruskal–Wallis 
tests as appropriate and categorical explanatory variables were 
reported as percentages and compared with χ2 tests or Fisher’s 
exact test, as appropriate. Multivariable analyses were based on 
negative binomial regression modeling for the LOS calculations 
(LOS expressed as a count of days) and on logistic regression 
modeling for binary outcomes. When investigating the associa-
tion between the presence of diabetes and other clinical factors, 
the statistically significant variables from the univariate analysis 
were included in a multivariable analysis. Standard diagnostics 
of model fit and collinearity (based on mean variance inflating 
factors and condition numbers) were conducted. All p values 
were calculated from two-tailed tests of statistical significance 
and p < 0.05 was regarded as statistically significance. All analyses 
were performed with Stata software V.13.0 (StataCorp, College 
Station, TX, USA).
resUlTs
A total of 335 psychiatry inpatients formed the study cohort. 
Fourteen percent of these patients (95% CI: 10–18%, n =  46) 
had diabetes, 19% (95% CI: 15–23%, n = 63) had pre-diabetes, 
and 67% (95% CI: 62–72%, n = 226) had no diabetes. Only two 
patients had new diagnosis of diabetes, and there were none with 
type 1 diabetes. The median HbA1c was 7.3% (IQR 6.2, 8.7) or 
56  mmol/mol (IQR 44, 72) in the diabetes group, 5.8% (IQR 
5.7–5.9) or 40 mmol/mol (IQR 39–41) in the pre-diabetes group, 
and 5.4% (IQR 5.2–5.5) or 36 mmol/mol (IQR 33–37) in the no 
diabetes group (Table 1).
Demographics
Compared to patients with pre-diabetes and no diabetes, patients 
with diabetes were predominantly older (median, IQR): age 49 
(39–62) versus those with pre-diabetes (age 46, IQR 36–55) and 
no diabetes (age 40, IQR 34–48) (p = < 0.001) (Table 1).
The proportion of psychiatry inpatients with diabetes by age 
group was disproportionately higher and skewed in the opposite 
direction toward younger age, compared to community diabetes 
prevalence (Figure 1) (14).
Patients with diabetes compared to those with pre-diabetes 
and no diabetes were more likely to be unemployed 89% 
(diabetes) versus 84% (pre-diabetes) and 73% (no diabetes) 
(p = 0.02) (Table 1). Patients with diabetes had a trend toward 
higher rates of substance abuse (37% for patients with dia-
betes versus 18% for patients with pre-diabetes and 23% for 
patients with no diabetes, p =  0.05). With regards to medical 
co-morbidities, patients with diabetes were almost twice as 
likely to have hypertension (22 versus 14 and 6%, p =  0.002), 
hyperlipidemia (28 versus 10 and 6%, p  ≤  0.001), obesity 
(44 versus 23 and 17%, p = 0.001) compared to those with pre-
diabetes and no diabetes, respectively (Table 1). However, in a 
number of inpatients, there was no record of weight (n = 125, 
37%), and in 34% (n  =  115), there was no record of lipid 
profile (Table 1).
The most common psychiatric diagnoses were schizophrenia, 
depression, and substance abuse across the three groups. A high 
percentage of patients in all the three groups had two or more 
psychiatric diagnosis or a diagnosis that was not classified in 
those broad categories (Table 2).
No statistically significant differences in duration of psychiat-
ric illness between the groups were identified between the three 
groups [diabetes group, median (IQR): 12  years (6–18), pre-
diabetes group: 10 years (4–19) versus no diabetes group: 9 years 
(3–18) (p = 0.215)] (Table 1).
Atypical antipsychotic medication use was similar across each 
of the three groups (42% in diabetes, 55% in pre-diabetes, and 
55% in no diabetes, p =  0.3) (Figure  2). No significant differ-
ences in the use of the different atypical antipsychotics between 
the diabetes, pre-diabetes, and no diabetes groups (0% in the 
diabetes group, 1% in the pre-diabetes group, and 5% in no 
Table 2 | The results of the multivariable logistic regression model 
investigating the association between independent variables with 
presence of diabetes compared to patients with pre-diabetes and no 
diabetes.
Diabetes versus pre-diabetes and no diabetes
clinical characteristics Odds ratio 95% confidence interval p-Value
Age 1.04 1.01–1.07 0.02
Schizoaffective disorder 0.18 0.02–1.36 0.1
Substance abuse 2.13 1.03–4.43 0.04
Aripiprazole use 4.4 1.51–12.83 0.01
Hypertension 1.26 0.46–3.45 0.65
Hyperlipidemia 2.88 1.14–7.26 0.03
Obesity 1.96 0.90–4.26 0.09
Employed 0.57 0.20–1.59 0.28
All p values were calculated from two-tailed tests of statistical significance and p < 0.05 
was regarded as statistically significant.
FigUre 1 | Percentage of adults with diagnosed diabetes by age group in the inpatient psychiatry population versus general age-matched 
population with diabetes. General age-matched population data are adapted from Australian Bureau of Statistics (14) and reproduced without permission.
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diabetes group, p = 0.2) were detected. No significant differences 
in the use of both typical and atypical antipsychotics between 
the diabetes, pre-diabetes, and no diabetes groups (15% in the 
diabetes group, 10% in the pre-diabetes group, and 11% in the no 
diabetes group, p = 0.4) were detected. No significant differences 
in the use of mood stabilizers across the three groups (18% in the 
diabetes group, 21% in the pre-diabetes group, and 24% in the 
no diabetes group, p = 0.2). No significant differences in the use 
of anti-depressants across the three groups (70% in the diabetes 
group, 63% in the pre-diabetes group, and 52% in the no diabetes 
group, p = 0.1) (Figure 2).
Univariate analysis of baseline 
characteristics and glycemic status
In order to highlight risk factors associated with the presence of 
diabetes, for the remaining analyses, we pooled patients with pre-
diabetes or no diabetes (n = 289, 86%) and compared to patients 
with diabetes (n =  46, 14%). Univariate analysis demonstrated 
that patients with diabetes were more likely to have a past history 
of substance abuse (37 versus 21%, p = 0.02), have a history of 
hypertension (22 versus 14 and 6%, p = 0.007), hyperlipidemia 
(28 versus 10 and 7%, p < 0.001), and obesity (44 versus 23 and 
17%, p =  0.012), and have raised gamma-glutamyltransferase 
(43% versus 28%, p = 0.0009) compared to those with pre- dia-
betes or no diabetes. Patients with diabetes were more likely to be 
older [diabetes: median age 47, IQR (37–58) versus pre-diabetes 
and no diabetes (median age 40), IQR (34–48)] and less likely to 
be employed (diabetes: 11% versus pre-diabetes and without dia-
betes: 25%, p = 0.02). Patients with diabetes were also more likely 
to be on the atypical antipsychotic aripiprazole (15 versus 5%, 
p = 0.02) compared to those with pre-diabetes and no diabetes. 
Compared to patients with diabetes, patients with pre-diabetes 
and no diabetes were more likely to have schizoaffective disorder 
FigUre 2 | Prevalence of baseline psychiatric medications among diabetes, pre-diabetes, and no diabetes groups.
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(12 versus 2%, p =  0.027) and other psychosis (10 versus 0%, 
p = 0.01).
Multivariable analysis
Multivariable logistic regression model investigating the asso-
ciations with presence of diabetes included age, diagnosis of 
schizoaffective disorder, past history of substance abuse, presence 
of hypertension, dyslipidaemia, obesity, use of aripiprazole, and 
employment status as independent variables. On this adjusted 
analysis (Mean VIF = 1.12, Condition Number = 11.4), greater 
age (OR per year 1.04, 95% CI: 1.01–1.07, p =  0.02), past his-
tory of substance abuse (OR 2.13, 95% CI: 1.03–4.43, p = 0.04), 
presence of dyslipidaemia (OR 2.88, 95% CI: 1.14–7.26, p = 0.03) 
and use of aripiprazole (OR 4.4, 95% CI: 1.51–12.83, p = 0.01), 
were all statistically significantly associated with the presence of 
diabetes (Table 2).
length of stay
The length of inpatient stay was longer in inpatients with diabetes 
when compared to pre-diabetes and no diabetes [median (IQR): 
29 days (14–81) in diabetes group versus 18 days (9–29) in the 
pre-diabetes and no diabetes group (p = 0.0006)]. In inpatients 
whose LOS was less than 400 days (this LOS chosen to exclude 
outliers), a multivariable negative binomial regression analysis 
was undertaken. There were 11 outliers (3% of total patients) 
with LOS above 417 days. Based on this analysis, a psychiatric 
patient with diabetes was expected to stay in hospital 70% longer 
(Incidence rate ratio, 1.7 95% CI: 1.2–2.3, p =  0.001) than a 
patient with pre-diabetes or no diabetes with the similar status 
on all the different psychiatric diagnosis including schizophrenia, 
schizoaffective disorder, bipolar affective disorder, depression, 
other psychosis, substance abuse, and eating disorders.
To further investigate robustness of these findings, we under-
took a similar analysis to determine the associations between 
diabetes status and LOS in patients who had admission for less 
than 90 days. Under this cutoff 30 patients were excluded (9% 
of the total number of patients). The results of this analysis were 
qualitatively similar. In those who had a LOS below 90  days, 
the multivariable negative binomial regression analysis model 
estimated that a psychiatric patient with diabetes trended toward 
a 30% longer LOS (Incidence Rate Ratio 1.3, 95% CI: 0.98–1.7; 
p = 0.07) than a patient with pre-diabetes or no diabetes with the 
similar status on all the different psychiatric diagnosis including 
schizophrenia, schizoaffective disorder, bipolar affective dis-
order, depression, other psychosis, substance abuse, and eating 
disorders.
DiscUssiOn
First, this study demonstrated high prevalence of pre-diabetes 
and diabetes in the inpatient psychiatry population, compared to 
age-matched rates of prevalence of diabetes in the general com-
munity. Second, diabetes was associated with a more prolonged 
psychiatric inpatient LOS. Third, increasing age and substance 
abuse were associated with higher rates of diabetes in the inpatient 
psychiatry population, independent of other risk factors. Fourth, 
diabetes was associated with lower employment rates. Fifth, in 
one-third of inpatients, weight and lipid profile was not recorded.
The rates of pre-diabetes and diabetes in this study were 19% 
and 14% respectively. Prior studies have similarly reported high 
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rates of diabetes in those patients with psychosis living in the 
community (6). In the current study, we demonstrate a snapshot 
of the glycemic status of the inpatient psychiatry population 
who are likely a more vulnerable group, with regards to higher 
psychiatric illness severity, chronic illness and disability.
In the current study, a longer duration of psychiatric illness 
was not associated with diabetes presence. A study of two epide-
miological databases of psychiatric inpatients over two different 
time periods did not find any association between diabetes and 
serious mental illness but reported an association between diabe-
tes and psychotropic treatment (15). The lack of association may 
be due to the small population size, the variety of mental health 
diagnosis, the short follow-up, and not accounting for confound-
ing factors (15).
There was a significant gender bias skewed toward males, 
representing approximately 70% of psychiatric inpatients. This 
finding is in line with previous studies demonstrating that males 
present with psychiatric disorders requiring admission (16).
The most prevalent psychiatry diagnosis in our patient cohort 
included schizophrenia, depression, and substance abuse, which 
are reflective of the disease burden in the acute inpatient psychiatry 
patient. Substance abuse has been described in previous studies to 
be associated with the development of diabetes through multiple 
mechanisms, including hyperglycemia, hyperinsulinemia, poor 
overall physical health, higher rates of psychological distress, 
poor compliance to psychotropic therapy, and increasing rate of 
mental health admissions (6, 7, 17). It is, therefore, challenging to 
pinpoint one factor alone in the development of diabetes.
Many studies have shown that use of atypical psychotropic 
therapy has been associated with weight gain, impaired glucose 
metabolism, and increased risk of metabolic syndrome (18). 
Contrary to previous studies, we did not find a significant associa-
tion between the type of psychotropic therapy patients received 
and prevalence of diabetes except in those inpatients who were 
taking aripiprazole. In fact aripiprazole has been shown in two 
studies to relate to a favorable metabolic profile (19, 20). Perhaps 
our data highlighted those individuals who were in the process 
of being transitioned to aripiprazole from a different psycho-
tropic agent and hence this association may reflect the severity 
of underlying psychiatric disease and longer prior duration of 
antipsychotic use.
Limitations of the current study include lack of long-term 
medication exposures, including drug dosage prior to admission. 
Lifestyle factors, such as smoking, alcohol consumption, and 
substance abuse, may be underreported or inaccurately recorded. 
Clinical variables, such as weight and lipid profile, were missing 
in a significant proportion of the inpatients, perhaps reflecting 
the difficulty of obtaining a thorough physical examination and 
full metabolic profile in vulnerable psychiatry inpatients as has 
been described in previous studies (21, 22). Due to the limited 
data on the clinical characteristics, we were not able to make a 
comment on the presence of the metabolic syndrome in the cur-
rent cohort. We were, therefore, not able to incorporate HbA1c 
into the revised definition of metabolic syndrome to enhance the 
detection of hyperglycemia (23). Additionally, ethnicity data was 
not routinely recorded.
Multivariable analysis highlighted variables associated with 
the presence of diabetes which may be useful in early flagging 
of those patients at highest risk of developing diabetes, namely, 
age, substance abuse, and presence of cardiovascular risk factors. 
Multivariable analysis also highlighted that patients with diabetes 
were more likely to have a longer length of inpatient psychiatry 
stay, suggesting perhaps that mental illness is more severe in 
people with diabetes.
However, given that this is an observational study, it is 
difficult to ascertain cause and effect. For example, the use of 
aripiprazole could reflect severity of mental illness and may be 
a confounder.
Current recommendations from Diabetes Australia are that 
individuals should be screened every 3 years from the age of 40 
(24). The only relevant reference to screening those with mental 
illness is that the guideline suggests screening inpatients on 
antipsychotic medication alone, not including other psychiatric 
medications. A consensus statement developed by the ADA in 
2004 discusses the screening for hyperglycemia in people treated 
specifically with antipsychotic medications (13). However, this 
may not capture other patients with mental illness who are on 
other psychiatric medications and may be at risk of developing 
diabetes. The New South Wales Health Clinical algorithm “Don’t 
Just Screen, Intervene” (25) recommends measurement of fast-
ing glucose or HbA1c every 3–6  months in people receiving 
antipsychotic medications, for early detection and intervention. 
The National Institute for Health and Care Excellence Guidelines 
recommend diabetes screening prior to commencement of 
antipsychotic medication, 3  months later, then annually (26). 
Over one-third of our patient group did not have a weight or 
lipid profile recorded at baseline. This is a significant proportion 
of patients who are not getting optimal screening and, therefore, 
not being provided with the opportunity for optimization of 
management. Our current hospital guidelines suggest screening 
for diabetes as well other metabolic parameters in any patient 
prescribed psychotropic medications regardless of age (27). 
However, the challenge is obviously in implementing these 
guidelines as well ongoing management of these patients due 
to their potential lack of insight and care secondary to their 
mental illness. Barriers to screening, diagnosis, and monitoring 
of physical conditions in patients with mental illness are mani-
fold and have already been described in many studies (28–31). 
Nevertheless, a hospital admission is an opportunity to screen 
for and initiate treatment of diabetes in all people with severe 
mental illness. Furthermore, it is an ideal opportunity to opti-
mize therapy in a setting where admissions are often protracted 
and education in diabetes self-care and diet can be initiated once 
the patients is sufficiently well.
Metformin coupled with a lifestyle intervention program 
has been proposed in people at high risk of diabetes for cardio-
metabolic protection as it has been shown to improve weight and 
metabolic parameters in normo-glycemic patients with psychosis 
commencing or receiving antipsychotic medication (32–34). 
Novel diabetic agents such as GLP-1 agonist are also being 
studied for management of diabetes and obesity in psychiatry 
populations on antipsychotic medications (35).
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cOnclUsiOn
The prevalence of type 2 diabetes and pre-diabetes in our inpa-
tient psychiatry population was high compared to age-matched 
rates of prevalence of diabetes in the general community and 
reflected the poor physical health of patients with mental illness. 
There was a strong association between increased age, lower 
employment rates, and substance abuse with the prevalence of 
diabetes, independent of other risk factors, as well prolonged 
inpatient LOS. While there are good guidelines for diagnosis and 
managing diabetes in these patients, one-third of our patients 
did not have appropriate cardio-metabolic screening as per our 
current guidelines. The challenges lie in health professionals 
implementing these guidelines due to a number of factors, 
including well-defined disparities in the delivery of health care 
to people with severe mental illness and bidirectional lack of 
engagement. The management of glycemic status in psychiatric 
inpatients following discharge may also be challenging and 
hence routine HbA1c testing as an inpatient presents an oppor-
tunity to address and improve glycemic management during the 
inpatient stay.
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